Ethics approval and consent to participate

This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center.

Consent for publication

All patients signed written informed consent for treatment, data collection and usage of data for clinical research in accordance with modified Declaration of Helsinki and Good Clinical Practice guidelines.

Competing interests

G.L.S. has research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, and GPCR, and is on the DSMB for ArcellX. G.S. has received in the last 12 months financial compensations for participating in advisory boards: Abbvie, Beigene, BMS, Genentech/Roche, Genmab, Incyte, Ipsen, Janssen, Kite/Gilead, Loxo/Lilly, Merck, Novartis, Nurix; has received in the last 12 months financial compensations consulting from: Abbvie, Atbtherapeutics, Beigene, BMS, Debiopharm, Genentech/Roche, Genmab, Incyte, Ipsen, Kite/Gilead, Molecular Partners, Nordic Nanovector, Novartis, Orna; he is also a shareholder of: Owkin; received research support managed by his institution from Genentech, Janssen, Ipsen, Nurix. M.E.M. received speaker honoraria from Siemens, General Electric, and Bristol Myers Squibb. All other authors report no competing interests. M.L.P received honoraria and research funding from BMS, Cellectar, Ceramedix, Juno, Kite, MustangBio, Garuda Therapeutics, Novartis, Pluto Immunotherapeutics, Rheos, Seres Therapeutics, Smart Immune, Thymofox, Synthekine, June and Seres. M.S. served as paid consultant for McKinsey & Company, Angiocrine Bioscience, Inc, and Omeros Corporation; received research funding from Angiocrine Bioscience, Inc., Omeros Corporation, and Amgen, Inc.; served on ad hoc advisory boards for Kite– A Gilead Company; and received honoraria from i3Health, Medscape, and CancerNetwork for CME-related activitiy. M.A.P. reports honoraria from Adicet, Allogene, Allovir, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Karyopharm, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Sanofi, Syncopation, VectivBio AG, and Vor Biopharma; serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences, and the scientific advisory board of NexImmune; has ownership interests in NexImmune, Omeros and OrcaBio; has received institutional research support for clinical trials from Allogene, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. All other authors declare that they have no competing interests.